Paratek Pharmaceuticals

Pharmaceuticals | January 04, 2017

According to Zacks, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, ...

PharmiWeb Solutions | February 08, 2017

Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that its President and Chief Operating Officer, Evan Loh, MD, will participate in the LEERINK Partners 6th Annual Global Healthcare Conference on Wednesday, February 15 with a fireside chat from 1:00 to 1:25 p.m. The conference is being held at the at the Lotte New York Palace Hotel in New York, New York. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycli...

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Business Wire Press Releases | January 16, 2020

Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...